Scoring systems that combine donor clinical and morphological parameters to predict outcome of kidney transplantation lack enough specificity to be generally accepted. Compare to classical histology, molecular assessment of renal tissue offers unbiased and technically robust approach. In this prospective 3-months' observational study procurement biopsies in 180 brain death donors will be performed. Using microarray which detect top differently regulated genes, conventional histology, urinary AKI biomarkers, renal function and clinical variables models predicting DGF and early graft scarring (IFTA, poor graft function) in recipients will be constructed. The associations of AKI in donors with distinct fibrosis atrophy and AKI molecular signals will be found. Molecular techniques and final models may help to improve the decision-making process for the acceptance of kidneys from marginal donors but more importantly, it may help clinicians to guide less toxic immunosuppression in identified problematic grafts.
The aim is to create a prediction model of early clinical outcome (delayed graft function) based on donor and recipient clinical variables, donor eGFR, urinary AKI biomarkers, histology (glomerulosclerosis, interstitial fibrosis, vascular changes) and top differently regulated genes found in microarray of wedge procurement donor biopsy. Construct a model capable to predict early renal allograft scarring (IFTA\>2), and impaired graft function (eGFR\<45 mL/min), as early as at 3 months. Describe renal molecular changes associated with established AKI in brain-death deceased donor and with aging.
Study Type
OBSERVATIONAL
Enrollment
200
Biomarkers of kidney damage in donors, such as neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-beta-D-glucosaminidase (NAG), beta2-microglobulin, alpha1-microglobulin, alpha2-macroglobulin and transferrin will be measured by ELISA.
Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
Institute for Clinical and Experimental Medicine
Prague, Czechia
Kidney graft function at month 3
Kidney graft function is measured as estimated glomerular filtration in ml/s/1.73m2.
Time frame: 3 months
Kidney graft survival
Measured as numbers of patients with graft loss censored to death.
Time frame: 1 year
Delayed graft function
The need of dialysis in the 1st week after transplantation. Measured as numbers of patients.
Time frame: 1 week
Fibrosis grade at month 3
Histologic result of interstitial fibrosis and atrophy at protocol biopsy. Min 0, Max 3, higher means worse
Time frame: 3 months
Gene expression in Donor kidney
Whole transcriptome microarray profiling of wedge biopsy taken immediately after organ procurement.
Time frame: 3 months
Gene expression in 3-month protocol biopsy of recipient
Whole transcriptome microarray profiling of 3-months protocol biopsies of recipients .
Time frame: 3 months
Urinary biomarkers of AKI in donors before organ taking
NGAL, Neutrophil gelatinase-associated lipocalin, ng/ml.
Time frame: 3 months
Urinary biomarkers of AKI in donors before organ taking (NAG)
NAG, N-acetyl-beta-D-glucosamine, in IU/l
Time frame: 3 months
Urinary biomarkers of AKI in donors before organ taking (beta 2 microglobulin)
beta 2 microglobulin, in mg/l
Time frame: 3 months
Urinary biomarkers of AKI in donors before organ taking (alfa1 microglobulin)
alfa1 microglobulin, in mg/l
Time frame: 3 months
Urinary biomarkers of AKI in donors before organ taking (alfa2 macroglobulin)
alfa2 macroglobulin, in mg/l
Time frame: 3 months
Urinary biomarkers of AKI in donors before organ taking (transferrin)
transferrin, in mg/l
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.